GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (NAS:VTRS) » Definitions » ROE %

VTRS (Viatris) ROE % : -6.60% (As of Jun. 2024)


View and export this data going back to 1986. Start your Free Trial

What is Viatris ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Viatris's annualized net income for the quarter that ended in Jun. 2024 was $-1,306 Mil. Viatris's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was $19,767 Mil. Therefore, Viatris's annualized ROE % for the quarter that ended in Jun. 2024 was -6.60%.

The historical rank and industry rank for Viatris's ROE % or its related term are showing as below:

VTRS' s ROE % Range Over the Past 10 Years
Min: -5.84   Med: 3.69   Max: 29.99
Current: -3.18

During the past 13 years, Viatris's highest ROE % was 29.99%. The lowest was -5.84%. And the median was 3.69%.

VTRS's ROE % is ranked worse than
67.53% of 964 companies
in the Drug Manufacturers industry
Industry Median: 4.275 vs VTRS: -3.18

Viatris ROE % Historical Data

The historical data trend for Viatris's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris ROE % Chart

Viatris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 -3.85 -5.84 10.00 0.26

Viatris Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.06 6.36 -14.82 2.25 -6.60

Competitive Comparison of Viatris's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viatris's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's ROE % distribution charts can be found below:

* The bar in red indicates where Viatris's ROE % falls into.



Viatris ROE % Calculation

Viatris's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=54.7/( (21072.3+20467.4)/ 2 )
=54.7/20769.85
=0.26 %

Viatris's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Mar. 2024 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=-1305.6/( (20014.3+19520)/ 2 )
=-1305.6/19767.15
=-6.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.


Viatris  (NAS:VTRS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-1305.6/19767.15
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-1305.6 / 15186.4)*(15186.4 / 46336.85)*(46336.85 / 19767.15)
=Net Margin %*Asset Turnover*Equity Multiplier
=-8.6 %*0.3277*2.3441
=ROA %*Equity Multiplier
=-2.82 %*2.3441
=-6.60 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-1305.6/19767.15
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-1305.6 / -1567.2) * (-1567.2 / -466.8) * (-466.8 / 15186.4) * (15186.4 / 46336.85) * (46336.85 / 19767.15)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8331 * 3.3573 * -3.07 % * 0.3277 * 2.3441
=-6.60 %

Note: The net income data used here is four times the quarterly (Jun. 2024) net income data. The Revenue data used here is four times the quarterly (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Viatris ROE % Related Terms

Thank you for viewing the detailed overview of Viatris's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Viatris Business Description

Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Executives
Rajiv Malik director, officer: President BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Brian Roman officer: Global General Counsel 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Anthony Mauro officer: See Remarks BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Paul Campbell officer: See Remarks BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Dillon Joellen Lyons director BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HARTFORDSHIRE X0 AL 109UL
Xiangyang (sean) Ni officer: President, Greater China 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Andrew Cuneo officer: See Remarks 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Leo Frans Groothuis director 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Scott Andrew Smith director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elisha W Finney director C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Van Der Meer Mohr Pauline director 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Menassie Taddese officer: See Remarks 1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Robert J Coury director, officer: Executive Chairman BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
W Don Cornwell director
James M Kilts director 120 PARK AVE, NEW YORK NY 10017